Abstract
Melanoma represents 2-3% of all cancers, 95% of them arise from skin, while only 5% are non-cutaneous melanoma. Despite an optimal surgery management, the risk of a local and systemic relapse remains high, particularly in high-risk patients (node-positive or node-negative T3b, T4 a/b). We conducted a systematic review of the main published and ongoing phase I/II/III trials between 2000 and June 2015 on the adjuvant treatment of cutaneous melanoma. The IFN remains the only option currently available for this aim. Ipilimumab represents a possible breakthrough in this setting, considering the positive results of the EORTC 18701 trials in terms of disease free survival (DFS), while data regarding OS are pending. Recent advances in the understanding of the biology of melanoma result in the identification of MAPK pathway role in the melanoma development.
Based on these features, B-RAF inhibitors and their combination with immunotherapy could represent the upcoming therapeutic strategy.
Keywords: Adjuvant treatment, biochemotherapy, immunotherapy, interferon, melanoma, radiotherapy, target therapy.
Current Cancer Drug Targets
Title:Melanoma Adjuvant Treatment: Current Insight and Clinical Features
Volume: 18 Issue: 5
Author(s): Carmine D`Aniello, Francesco Perri, Giuseppina Della Vittoria Scarpati, Chiara Della Pepa, Salvatore Pisconti, Vincenzo Montesarchio, Nicolas Wernert, Mayra Rachele Zarone, Michele Caraglia, Gaetano Facchini*, Massimiliano Berretta and Carla Cavaliere
Affiliation:
- Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Naples,Italy
Keywords: Adjuvant treatment, biochemotherapy, immunotherapy, interferon, melanoma, radiotherapy, target therapy.
Abstract: Melanoma represents 2-3% of all cancers, 95% of them arise from skin, while only 5% are non-cutaneous melanoma. Despite an optimal surgery management, the risk of a local and systemic relapse remains high, particularly in high-risk patients (node-positive or node-negative T3b, T4 a/b). We conducted a systematic review of the main published and ongoing phase I/II/III trials between 2000 and June 2015 on the adjuvant treatment of cutaneous melanoma. The IFN remains the only option currently available for this aim. Ipilimumab represents a possible breakthrough in this setting, considering the positive results of the EORTC 18701 trials in terms of disease free survival (DFS), while data regarding OS are pending. Recent advances in the understanding of the biology of melanoma result in the identification of MAPK pathway role in the melanoma development.
Based on these features, B-RAF inhibitors and their combination with immunotherapy could represent the upcoming therapeutic strategy.
Export Options
About this article
Cite this article as:
D`Aniello Carmine, Perri Francesco, Scarpati Della Vittoria Giuseppina, Pepa Della Chiara, Pisconti Salvatore, Montesarchio Vincenzo, Wernert Nicolas, Zarone Rachele Mayra, Caraglia Michele, Facchini Gaetano*, Berretta Massimiliano and Cavaliere Carla, Melanoma Adjuvant Treatment: Current Insight and Clinical Features, Current Cancer Drug Targets 2018; 18 (5) . https://dx.doi.org/10.2174/1568009617666170208163714
DOI https://dx.doi.org/10.2174/1568009617666170208163714 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Structural Determinants that Lead to the Formation of Particular Oligomeric Structures in the Pancreatic-Type Ribonuclease Family
Current Protein & Peptide Science Recent Developments in Skin Mimic Systems to Predict Transdermal Permeation
Current Pharmaceutical Design Computed Tomography in the Diagnosis of Ascites: The Role of Fluid Attenuation Values
Current Medical Imaging Enhanced Antioxidant and Protective Activities on Retinal Ganglion Cells of Carotenoids-Overexpressing Transgenic Carrot
Current Drug Targets Effectiveness of Resveratrol Against Cardiovascular Disease
Mini-Reviews in Organic Chemistry Antioxidant Effect of Flavonoids Present in Euterpe oleracea Martius and Neurodegenerative Diseases: A Literature Review
Central Nervous System Agents in Medicinal Chemistry The Management of Metastatic Bone Disease with the Combination of Bisphosphonates and Radiotherapy: From Theory to Clinical Practice
Anti-Cancer Agents in Medicinal Chemistry ADAM Proteases: Protective Role in Alzheimers and Prion Diseases ?
Current Alzheimer Research Anticancer Activity and Anti-inflammatory Studies of 5-Aryl-1,4-benzodiazepine Derivatives
Anti-Cancer Agents in Medicinal Chemistry Enhanced Activity of pSTAT-3 Ser-727 in Functional Endothelial Cells Under Calcifying Conditions
Current Chemical Biology Role of ABC Transporters in Veterinary Medicine: Pharmaco- Toxicological Implications
Current Medicinal Chemistry Subject Index to Volume 5
Current Drug Targets Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6
Current Drug Metabolism Recent Advances in Efficacy of using Doxorubicin Gold Nanoparticles for Chemo-, Radio-, Photothermal, and Photodynamic Therapy
Current Drug Delivery Perspectives On Membrane-associated Progesterone Receptors As Prospective Therapeutic Targets
Current Drug Targets Peptides in Melanoma Therapy
Current Pharmaceutical Design Synthesis and In Vitro Antitumor Effect of New Vindoline-steroid Hybrids
Current Organic Chemistry Stem Cells and the Side Population Theory: A Critical Review
Current Tissue Engineering (Discontinued) Glioma Stem Cell Maintenance: The Role of the Microenvironment
Current Pharmaceutical Design Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications
Current Pharmaceutical Design